Table 1 Summary of included studies
Study | Phase | Treatment | Number of subjects randomized/ treated | Treatment period, weeks | Insulin titration schedule |
|---|---|---|---|---|---|
EASIE [35] | 3b/4 | Gla-100 + MET vs. SITA + MET | 515/501 | 24 | Twice weekly |
4020 [36] | 3b | Gla-100 + SU or MET vs. PIO + SU or MET | 389/382 | 24 extended to 48 | Weekly |
4022 [37] | 3b | Gla-100 + SU or MET vs. TZD + SU + MET | 337/334 | 24 extended to 48 | Weekly |
L2T3 [38] | 4 | Gla-100 + OADs vs. DET + OADs | 973/964 | 24 | Every 2 days |
IN-SIGHT [39] | 3b | Gla-100 + current OADs vs. current OADs | 405/400 | 24 | Daily |
4001 [40] | 3b | Morning vs. bedtime Gla-100 + morning GLIM vs. NPH insulin bedtime + morning GLIM | 700/697 | 24 | Weekly |
4013 [41] | 3b | Gla-100 bedtime + morning GLIM vs. NPH insulin bedtime + morning GLIM | 528/481 | 24 | Weekly |
4002 [42] | 3b | Gla-100 bedtime + OADs vs. NPH insulin bedtime + OADs | 764/756 | 24 | Weekly |
4014 [43] | 4 | Gla-100 + SU + MET vs. ROS + SU + MET | 219/217 | 24 | Weekly |
4021 [44] | 3b | Gla-100 + SU + MET vs. LIS 75/25 + SU + MET | 212/212 | 24 | Weekly |
4041 [45] | 4 | Gla-100 with group education + OADs vs. Gla-100 with individual education + OADs | 121/121 | 24 | Self-titration, then investigator reviewed at each visit |